NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Denali Therapeutics Inc. Common Stock (DNLI) Stock Analysis

Denali Therapeutics Inc. Common Stock (DNLI) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

DNLI

$18.68

−$0.25 (−1.32%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare DNLI with… →

DNLI Key Statistics

As of Oct 21, 2026
Trading
Open
$18.93
Previous Close
$18.93
Day's Range
18.58–19.13
52-Week Range
13.75–27.30
Volume
1.43M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.02
Valuation
Market Cap
$2.99B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
828.51
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.84
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$512.54M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
159.85M
1-Year Return
+10.14%
Dividend and dates
Earnings Date
November 5, 2026
Avg Volume
1.59M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, DNLI closed at $18.68, +10.14% over 1 year.

Denali Therapeutics Inc. Common Stock (DNLI) has a market capitalization of $2.99B.

In fiscal 2025, DNLI reported revenue of $0.00.

DNLI Stock Return by Calendar Year

Denali Therapeutics Inc. Common Stock (DNLI) return since Dec 2017: what $10,000 became

1 year
$10,000 $11,014
+10.14%
5 years
$10,000 $4,046
−59.54%
Since Dec 2017
$10,000 $8,709
−12.91%

If you had invested $10,000 in Denali Therapeutics Inc. Common Stock (DNLI) at the close on December 8, 2017, the earliest close on record here, it would have been worth $8,709 at the close on October 21, 2026: −12.91% in total, −1.55% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+13.14%
2025−18.99%
2024−5.03%
2023−22.83%
2022−37.65%
2021−46.75%
2020+380.83%
2019−15.68%
2018+32.10%
2017 (partial year)−27.09%

As of October 21, 2026.

DNLI Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$512.54M—
2024$0.00−$422.77M—
2023$330.53M−$145.22M−43.9%
2022$108.46M−$325.99M−300.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$555.34M−$512.54M—
2024$0.00—−$501.88M−$422.77M—
2023$330.53M—−$196.70M−$145.22M−43.9%
2022$108.46M—−$340.74M−$325.99M−300.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

DNLI Valuation vs Biotechnology Median

Median of 608 stocks
MetricDNLIBiotechnology medianvs median
P/S ratio828.5113.3062.3x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 13 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Denali Therapeutics Inc. Common Stock (DNLI) at $2.99B. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 503.

The most recent close on file for DNLI is $18.68, dated October 21, 2026. That is −$0.25 (−1.32%) against the previous close. Over the past 52 weeks the price has ranged from $13.75 to $27.30. The latest close sits 35.85% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $512.54M. Trailing earnings per share are −2.84.

Across the 4 fiscal years on file, revenue moves from $108.46M in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 828.51 times revenue. On price-to-sales that is 62.3 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

The reported beta is 1.02. Annualized volatility over the trailing 8 years is 64.79%. The trailing one-year total return is +10.14%. Across 5 years the annualized return works out at −16.55%.

Growth & Income

No dividend is on file for DNLI.

The strongest complete calendar year on file is 2020 at +380.83%; the weakest is 2021 at −46.75%. Of the 8 complete calendar years on file, 2 finished higher. So far in 2026 the total return is +13.14%.

Peer Comparison

Denali Therapeutics Inc. Common Stock (DNLI) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Denali Therapeutics Inc. Common Stock DNLI $2.99B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Denali Therapeutics Inc. Common Stock has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Denali Therapeutics Inc. Common Stock

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Visit website →